Rebirthel

Rebirthel, founded in Kyoto, Japan in October 2019, is a biotechnology firm operating in the field of cellular immunotherapy. The company was established as a spin-off from Regcell, inheriting all projects and intellectual properties related to killer T cells. The scientific foundation of Rebirthel is built upon the work of Professor Hiroshi Kawamoto of Kyoto University, who, in 2013, was the first to successfully regenerate antigen-specific killer T cells from induced pluripotent stem (iPS) cells. Professor Kawamoto, a physician by training with a deep background in hematology and immunology, now serves as the company's founder and CTO, guiding its scientific strategy.

The company's core business revolves around developing and commercializing a novel allogeneic T-cell therapy. This approach addresses significant limitations of current autologous T-cell therapies, which are often costly, time-consuming, and variable in quality as they rely on the patient's own cells. Rebirthel's proprietary and globally patented technologies enable the mass production of killer T cells from a universal source of iPS cells. This allows the creation of "off-the-shelf" T-cell preparations that can be cryopreserved and made available to patients immediately and at a lower cost. The technology can produce various types of T cells, including highly cytotoxic killer T cells, to target a wide range of antigens.

Rebirthel's primary market is the treatment of diseases where the immune system plays a key role, with an initial focus on cancers that are difficult to cure with standard therapies. The company is preparing for a clinical trial for leukemia at Kyoto University. Beyond oncology, the technology has potential applications for viral infections, autoimmune diseases, and allergies. Rebirthel's business model includes forming strategic partnerships and licensing its technology. A notable collaboration is an exclusive commercial licensing agreement with Otsuka Pharmaceutical, granting them the right to use Rebirthel's technology for generating iPS cell-derived CAR-T/TCR-T therapies across multiple therapeutic areas worldwide. This agreement involves an upfront payment, milestone payments, and sales-based royalties to Rebirthel.

Keywords: cellular immunotherapy, T-cell therapy, iPS cells, regenerative medicine, oncology, cancer treatment, allogeneic therapy, off-the-shelf therapeutics, CAR-T, TCR-T, pluripotent stem cells, Hiroshi Kawamoto, Kyoto University, leukemia treatment, autoimmune diseases, viral infections, cell-based therapies, biotechnology, drug discovery, proprietary technology